Skip to content

Intensive Prevention Program After Myocardial Infarction

Intensive Longterm Prevention Program After Myocardial Infarction in Northwest Germany

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01896765
Acronym
IPP
Enrollment
300
Registered
2013-07-11
Start date
2013-10-31
Completion date
2020-05-31
Last updated
2020-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Prevention Harmful Effects

Brief summary

It is unknown, if a modern prevention program, including intense nurse-coordinated education sessions, regular telephone contacts and a telephone hotline for 12 months, significantly reduces cardiovascular risk factors, clinical events and quality of life in myocardial infarction patients compared to usual care. Furthermore, actually no data on the additional effects and the feasibility of longterm telemetric care of cardiovascular risk factors exist. The primary hypothesis to be tested is that an intensive longterm prevention program compared to the standard of medical care, will achieve better risk factor control and consecutively less clinical adverse events in patients after myocardial infarctions. The study endpoints will be evaluated after 12 months and during long-term course (after 24 months = one year after termination of the prevention program). In a substudy the effects of short reinterventions (Prevention Boosts) during long-term course are tested (IPP Prevention Boost Study). Patients with at least one insufficiently controlled risk factor at 24-months visit are randomly assigned to a short (2-month) reintervention vs. no reintervention. The effects of the reinterventions on risk factor control are evaluated after 36 months. A further substudy focusing on young patients \<= 45 years of age at time of MI (IPP-Y = IPP in the Young) was added after completion of the pilot IPP study. In this study we focus on the prevention program in young MI-patients. A retrospective analysis of individual genetic risk (assessed by genetic risk scores) in the young patients is included in this substudy.

Interventions

BEHAVIORALIntensive Prevention Program

Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available).

OTHERStandard medical and interventional therapy

Medical and interventional therapy following the standard of care.

Sponsors

Oldenburger Forschungs- und Entwicklungsinstitut für Informatik (OFFIS).
CollaboratorUNKNOWN
University of Luebeck
CollaboratorOTHER
Klinikum Oldenburg gGmbH
CollaboratorOTHER
Herzzentrum Bremen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Hospitalisation due to myocardial infarction (ST-elevation or non-ST-elevation myocardial infarction)

Exclusion criteria

i) Hemodynamically significant valvular heart disease (\> NYHA class II) or inborn cardiac malformations. ii) Cardiomyopathy associated with hemodynamic obstruction, pregnancy or myocarditis. iii) Exercise limitations due to clinical conditions not related to CAD. iv) Any major non-cardiac condition that would adversely effect survival during the duration of the study. v) Patients unlikely to comply to the study treatment and the follow-up visits. vi) Pregnancy (all pre-menopausal females should have a negative serum pregnancy test). vii) Inability of cooperation with the protocol, including longterm follow-up. viii) Patient refusal or inability to give informed consent. ix) Refusal of the patient's physician regarding trial participation of the patient. x) Chronic drug or alcohol abuse.

Design outcomes

Primary

MeasureTime frameDescription
Prevention score (point score of cardiovascular risk factors)24 months
Prevention success24 monthsImprovement of one of the risk factors LDL-cholesterol, physical inactivity, smoking without deterioration of another (primary endpoint for IPP-Y = substudy on young MI-patients \<= 45 years that was added after completion of the pilot study)

Secondary

MeasureTime frame
Combined endpoint of clinical adverse events24 months
Adherence to prognostic relevant medication after myocardial infarction24 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026